Literature DB >> 12048036

Humoral immune responses to microbial infections in the genital tract.

Michael W Russell1, Jiri Mestecky.   

Abstract

Human reproductive tracts represent components of the mucosal immune system with unique features. Although secretory IgA is present, IgG is more abundant, and typical mucosa-associated lymphoid tissue for generating common mucosal immune responses is absent. Antibody responses to genital infections or to locally applied vaccines are usually modest, but alternative strategies for eliciting genital tract antibodies are being developed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048036     DOI: 10.1016/s1286-4579(02)01585-x

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  48 in total

1.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

2.  Antiviral antibodies and T cells are present in the foreskin of simian immunodeficiency virus-infected rhesus macaques.

Authors:  Kristina Rothaeusler; Zhong-Min Ma; Huma Qureshi; Timothy D Carroll; Tracy Rourke; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

4.  Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

Authors:  Milan Raska; Zina Moldoveanu; Jan Novak; Zdenek Hel; Lea Novak; Jadranka Bozja; Richard W Compans; Chinglai Yang; Jiri Mestecky
Journal:  Vaccine       Date:  2008-02-07       Impact factor: 3.641

5.  Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice.

Authors:  Gregory A Price; Heather P Masri; Aimee M Hollander; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Vaccine       Date:  2007-08-06       Impact factor: 3.641

6.  Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens.

Authors:  Daniel O Ochiel; John V Fahey; Mimi Ghosh; Severina N Haddad; Charles R Wira
Journal:  Curr Womens Health Rev       Date:  2008-05

Review 7.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

8.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

9.  A comparative analysis of gene expression patterns and cell phenotypes between cervical and peripheral blood mononuclear cells.

Authors:  Rachel E Horton; Nadine Kaefer; Elijah Songok; Fernando B Guijon; Nadia Kettaf; Geneviève Boucher; Rafick-Pierre Sekaly; T Blake Ball; Frank A Plummer
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

10.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.

Authors:  Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson
Journal:  Vaccine       Date:  2009-09-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.